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Sarcoidosis is a granulomatous inflammatory disorder of unclear etiology, which is known
to affect multiple organ systems including the lungs, heart, skin, central nervous system,
and eyes, among others. For this reason, sarcoidosis represents a systemic medical disor-
der that is clinically relevant to multiple medical sub-specialties. Despite extensive research,
the etiology of sarcoidosis has yet to be elucidated, although most evidence supports that
the pathogenetic mechanism of sarcoidosis is an aberrant immune response, driven by an
unidentified antigen (or antigens) in genetically susceptible individuals. Multiple candidate
etiologic agents, including microbial organisms and environmental agents, have been in-
vestigated, but study results are inconclusive. In this review, we describe the known histo-
logic and immunologic features of sarcoidosis and discuss the evidence supporting a role
for infectious processes in the pathogenesis of sarcoidosis.
introduction
Sarcoidosis is a granulomatous multi-
system disorder of unclear etiology that
most commonly affects the lungs, heart,
skin,  and  central  nervous  system.  Sar-
coidosis in general represents a diagnostic
challenge, as clinical manifestations of the
disease are protean. Aside from this, the di-
agnosis of sarcoidosis is further hindered
by the lack of any reliable and specific di-
agnostic test, as there are no laboratory or
imaging findings that enable the definitive
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tologic findings associated with sarcoidosis
are non-specific, emphasizing the need to in-
terpret  histology,  when  obtained,  within
clinical  context.  Isolated  non-pulmonary
sarcoidosis poses even further diagnostic
challenges, with a general reluctance among
physicians to obtain extra-pulmonary biop-
sies (other than of the skin) on account of
the potential complications associated with
these procedures. Once the diagnosis of sar-
coidosis is made, management may range
from observation to administration of long-
term steroids (often at high doses) or other
immunosuppressive therapies, depending on
disease severity and organ involvement [1].
A genetic predisposition to sarcoidosis
is evidenced epidemiologically by demon-
stration of familial aggregation, differences
in disease susceptibility and severity between
racial groups, and the significantly increased
incidence in monozygotic twins of affected
individuals compared to other siblings [2-4].
Candidate gene and genome-wide associa-
tion studies have identified multiple genes
involved in the immune response to be re-
sponsible for this increased susceptibility to
sarcoidosis [5]. Specific gene alleles also
have been shown to be associated with dif-
ferent disease phenotypes [6].
It is hypothesized that sarcoidosis arises
in genetically susceptible hosts from interac-
tion with a single or multiple environmental
factors. Multiple potential etiologic agents
for sarcoidosis have been proposed without
any definitive demonstration of causality. An
enduring hypothesis is that of an infectious
etiology, with Mycobacterium spp. being the
most commonly implicated organism. The
role of various non-infectious, organic, and
inorganic  environmental  agents  has  been
studied in the pathogenesis of sarcoidosis.
The ACCESS† (A Case Control Etiologic
Study of Sarcoidosis) study, despite its in-
ability to definitively identify or determine a
sole cause of sarcoidosis, provided evidence
that certain environmental and occupational
exposures increase the risk for developing
sarcoidosis, although this risk is thought to
be modest at best [7,8]. An important diffi-
culty in identifying an etiologic agent under-
lying sarcoidosis is its wide variety of clini-
cal manifestations, which must be reconciled
with the complex immunologic processes
underpinning the disease.
HiStologic findingS in 
SarcoidoSiS
The histologic hallmark of sarcoidosis,
irrespective of organ involvement, is non-
caseating epithelioid granulomas. Granulo-
mas typically consist of a compact central
area of macrophages that differentiate into
epithelioid cells and then fuse to form multi-
nucleated giant cells surrounded by lym-
phocytes [1]. Schaumann’s bodies, asteroid
bodies, birefringent crystals, and Hamazaki-
Wesenberg bodies may all be present but are
non-specific. Lymphocytes scattered within
granulomas tend to be CD4+ T helper cells,
while those around the periphery are pre-
dominantly CD8+ T cells, as well as B cells.
There is generally minimal necrosis within
sarcoid granulomas, unlike those associated
with Mycobacterium tuberculosis infection
[9]. Currently, it is thought that granulomas
in  sarcoidosis  form  around  and  isolate
poorly degraded antigen as a means of pre-
venting antigen dissemination and further
tissue damage. While this hypothesized anti-
gen in sarcoidosis has not been identified,
possibilities include environmental antigens
and microbial remnants. Importantly, the de-
tection of granulomas alone are not specific
enough to diagnose sarcoidosis, and due to
the lack of any definitive diagnostic test, the
diagnosis of sarcoidosis is conventionally
governed by the appropriate combination of
clinical, histologic, and radiologic findings.
The demonstration of granulomas histolog-
ically (when biopsies are performed) mainly
serves to support the diagnosis of sarcoido-
sis, rather for its definitive confirmation, as
well as to exclude other potential etiologies
from the differential diagnosis.
immunoPatHogEnESiS of 
SarcoidoSiS
The  majority  of  immunologic  data
available on sarcoidosis are derived from
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commonly  affects  the  lungs,  although  it
should be borne in mind that sarcoidosis
does have the capacity to afflict extra-pul-
monary organs, sometimes without evidence
of concomitant pulmonary involvement. Pa-
tients with pulmonary sarcoidosis have in-
creased  cellularity  of  bronchoalveolar
lavage (BAL) fluid, with a predominance of
CD4+ T helper cells [10]. T helper cell acti-
vation is a requisite for granuloma formation
and further clinical evidence that CD4+ T
cells play a pivotal role in the pathophysiol-
ogy of sarcoidosis is demonstrated by the
tendency of HIV patients with sarcoidosis to
have CD4 counts greater than 200 cells/ʼL.
Also, patients with sarcoidosis who acquire
HIV generally do not demonstrate progres-
sion of their underlying sarcoidosis [11].
There are several studies demonstrating that
the T cell response in sarcoidosis-affected
tissues  is  strongly  polarized  toward  a  T
helper 1 (Th1) cytokine profile. Expression
of IFN-ʳ, IL-2, IL-12, TNF-ʱ, and other cy-
tokines consistent with a Th1 phenotype is
upregulated at sites of inflammation in sar-
coidosis [12].  
IL-2 is a potent inducer of T cell prolif-
eration and IFN-ʳ production and thus plays a
key role in the immune response of sarcoido-
sis. Furthermore, administration of IL-2 or
IFN-ʱ  (cytokines  that  promote  a  Th1  re-
sponse) has been shown to be associated with
new-onset sarcoidosis, or exacerbation of pre-
existing disease [13,14]. Increased IL-12 lev-
els  in  BAL  fluid  as  well  as  increased
production by alveolar macrophages also have
been reported in sarcoidosis [15,16]. IL-12
promotes Th0 differentiation into Th1 cells
and promotes activated natural killer (NK) cell
and T cell proliferation. It also enhances NK
and T cell mediated cytotoxicity and is a po-
tent stimulator of IFN-ʳ production [17,18].
Thus, IL-12 plays a critical role in the im-
munologic response to intracellular organisms
such as Mycobacterium tuberculosis, Toxo-
plasmosis gondii, and Listeria monocytogenes
[19-22]. Those with genetic defects in the IL-
12/IL12R (receptor) system have diminished
granuloma formation and are prone to atypical
mycobacterial infections [23].
Increased production of tumor necrosis
factor alpha (TNF-ʱ), a non-specific but po-
tent pro-inflammatory cytokine secreted by
a variety of immune cells, has been docu-
mented  in  sarcoidosis  [24,25].  In  mouse
models of mycobacterial infection, TNF-ʱ
and IFN-ʳ appear to drive granuloma for-
mation, and inhibition of either of these cy-
tokines results in diminished capacity for
granuloma formation [26,27]. Thus, TNF-ʱ
has been proposed as a target for therapy in
sarcoidosis, and the use of TNF-ʱ inhibitors
has been investigated for the treatment of
sarcoidosis, but results of clinical trials are
conflicting [28]. Understanding the role of
TNF-ʱ in the pathophysiology of sarcoido-
sis and TNF-ʱ inhibitors as potential thera-
peutic  agents  is  further  complicated  by
multiple cases of paradoxical development
of granulomatous disease following therapy
with TNF-ʱ inhibitors that have been re-
ported [29]. 
Another key feature of the immunologic
response in sarcoidosis is illustrated by the
finding that at sites of inflammation in sar-
coidosis, T cells exhibit a restricted T cell re-
ceptor  (TCR)  repertoire,  shown  to  be
consistent  with  oligoclonal  expansion,
strongly suggesting an antigen-specific re-
sponse [12,30-33]. The Kveim test, now sel-
dom  used  clinically,  can  offer  further
immunologic insight. Intradermal injection of
the Kveim reagent (consisting of spleen or
lymph  node  extracts  from  sarcoidosis  pa-
tients) induces localized granuloma formation
in 50 percent to 80 percent of sarcoidosis pa-
tients early in the disease process [34]. Fur-
thermore, the site of the Kveim reaction is also
infiltrated by CD4+ T cells with restricted
TCR heterogeneity [35]. BAL or peripheral
blood monocyte preparations are also capable
of inducing a similar reaction [36]. These
findings strongly support that sarcoidosis is
caused by an antigen-specific immune re-
sponse, with mononuclear phagocytes possi-
bly responsible for systemic dissemination of
the responsible agent. 
In contrast to the previously described
immune response present locally at sites of
inflammation, a paradoxical state of anergy
in the periphery exists, as evidenced by de-
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persensitivity  tests,  as  well  as  decreased
lymphocyte counts in the peripheral blood
of sarcoidosis patients, especially during pe-
riods of increased disease activity [37,38].
The mechanism of this peripheral anergy is
unclear, although it appears that T regulatory
cells may play an important role [39].
Given the immune profile previously
described and evidence supporting a famil-
ial  predisposition  to  sarcoidosis,  the  im-
munogenetic  background  of  sarcoidosis
patients has been heavily studied. Alleles of
genes involved in antigen presentation, cell
signaling, and other immune functions have
been reported to influence susceptibility to
the disease, as well as disease course and
prognosis. Multiple human leukocyte anti-
gen (HLA) gene alleles have most consis-
tently  been  shown  to  be  linked  to
sarcoidosis. Non-HLA genes associated with
sarcoidosis also include cytokine (notably
TNF gene polymorphisms), toll-like recep-
tor, chemokine receptor genes, and others
[5,6]. These observations suggest that aber-
rations at multiple levels of the immune re-
sponse may lead to the disease and that
immunogenetic variability may account for
the heterogeneity of disease manifestations
and course. Notably though, with the excep-
tion of TNF and HLA, candidate-gene asso-
ciation  studies  of  immune-related  genes
showing positive associations in populations
have not been widely replicated [40]. This
may signify that the genetic background that
confers susceptibility to sarcoidosis differs
between  different  populations,  thus  ac-
counting (most likely in combination with
environmental factors) for geographic and
racial variation in disease incidence and phe-
notype.
PotEntial infEctiouS
PatHogEnS
One enduring etiologic hypothesis for
sarcoidosis is that of an infectious etiology.
Multiple pathogens have been investigated
and implicated in the etiology of sarcoido-
sis, mainly Mycobacterium, although other
microbial agents also have been suggested
to play a role. Furthermore, findings of the
ACCESS study support that conditions of
possible exposure to microbial bioaerosols
are associated with sarcoidosis [7]. The im-
munologic features typical of sarcoidosis
also support this infectious etiologic hy-
pothesis,  but  the  evidence  for  specific
pathogens varies significantly.
Mycobacterium
Mycobacteriumhas been the longest hy-
pothesized and most investigated potential
etiology of sarcoidosis, due to the histologic
similarity between tuberculosis and sarcoido-
sis. Cultures and acid-fast stains of sarcoid
specimens classically do not demonstrate the
presence of mycobacterial organisms. Some
immunohistochemical studies have demon-
strated possible cell wall deficient mycobac-
terial remnants [41]. The mycobacterial cell
wall  component  tuberculostearic  acid  has
been  identified  in  some  specimens  [42].
However,  these  findings  have  not  been
widely confirmed. Nonetheless, the use of
techniques such as polymerase chain reaction
(PCR) and enzyme-linked immunospot assay
(ELISPOT) have demonstrated increasing
evidence supporting a role of Mycobacterium
in sarcoidosis. Studies investigating the pres-
ence of mycobacterial DNA or RNA in sar-
coidosis tissue have yielded positive results
in a range from 0 to 80 percent of specimens.
Meta-analyses of such studies suggests that
in 26 percent of sarcoidosis tissues, there is
evidence of mycobacterial nucleic acid, in-
sinuating a connection between sarcoidosis
and mycobacterial infection, a 9- to 19-fold
increased odds compared to non-sarcoidosis
controls [43]. More recent studies have iden-
tified Mycobacterium tuberculosis DNA for
the protein mKatG (Mycobacterium tubercu-
losis catalase-peroxidase protein) in 38 per-
cent of biopsy specimens and evidence for
circulating IgG to mKatG in almost half of
sarcoid patients investigated [44]. Further-
more, sarcoidosis patients have an increased
frequency of peripheral blood and lung T-cell
responses to mKatG and other mycobacterial
antigens  compared  to  healthy  controls
[45,46]. The lack of active mycobacterial in-
fection in sarcoidosis patients, either pre- or
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action rather than presence of an active or la-
tent  infection  following  exposure  to  the
organism [47]. However, it must be borne in
mind that the mere presence or detection of
mycobacterial antigens within sarcoid speci-
mens  does  not  substantiate  proof  of  any
causal relationship. Also, it is difficult to rec-
oncile Mycobacterium as the sole “cause” of
sarcoidosis, given that mycobacterial nucleic
acid or other mycobacterial antigens are not
detected in many sarcoid specimens. On the
other hand, with multiple studies utilizing dif-
ferent methods substantiating an association
between  mycobacterial  exposure  and  sar-
coidosis, a plausible hypothesis is that, in a
subset of patients, mycobacterial organisms
are an important contributing factor to the
pathogenesis of the disease. 
Propionibacterium
Propionibacterium acnes, a commensal
bacterium predominantly of the cutaneous
flora, is another organism that has been im-
plicated in sarcoidosis. Notably, it has been
shown that it is capable of inducing a gran-
ulomatous reaction in some experimental
models [48]. P. acnes has been cultured from
up to 78 percent of sarcoidosis samples, a
finding that has been confirmed by different
groups [49,50]. Additional evidence for a
pathogenic role is that an antibody response
to a P. acnes protein has been demonstrated
in 40 percent of sarcoidosis samples ob-
tained through BAL, as compared to 5 per-
cent in healthy controls [51]. However, this
commensal organism also has been found in
a large proportion of control tissues (up to
57 percent) [52]. This calls into question the
role of P. acnes as a true pathogenic organ-
ism in sarcoidosis, but interactions may exist
between P. acnes and other factors to pro-
mote inflammation in sarcoidosis.
Viruses and other infectious pathogens
Viral infection has been proposed as a
possible initiating factor in sarcoidosis with
several different viruses being implicated
based on serologic evidence, notably the
herpes viruses [53]. An important limitation
of this hypothesis is that viruses are not
known to cause the epithelioid granulomas
typical of sarcoidosis [47]. While antibodies
to  a  variety  of  these  viruses  have  been
demonstrated in sarcoidosis patients, there
is also a significant proportion of the gen-
eral population with previous exposure to
these organisms. Also, non-specific poly-
clonal hypergammaglobulinemia is a feature
of sarcoidosis and may account for increased
antibody titers to these viruses [54]. While
antibody-antigen  complexes  could  hypo-
thetically serve as a trigger for granuloma
formation, this has never been demonstrated
with respect to viruses. Molecular mimicry
following virus exposure also lacks a known
mechanism for granuloma formation, mak-
ing this a less likely pathogenesis.
Other pathologic organisms, especially
cell wall deficient forms of mycobacteria,
have  been  implicated,  predominantly
through case report observations, but none
have been widely confirmed. Recently, the
ACCESS study identified these organisms
in healthy controls as frequently as in sar-
coidosis patients, calling into question any
potential link with sarcoidosis [55].
Active vs. latent infection
If the etiology of sarcoidosis is truly re-
lated to an infectious agent, a key question is
whether this is an active or latent infection
or, alternatively, whether sarcoidosis repre-
sents an aberrant reaction to remnants of a
previously, but only partially, cleared organ-
ism. An important clue regarding these ques-
tions is the successful use of (often chronic)
corticosteroids and other immunosuppres-
sive therapies in the management of sar-
coidosis. Despite proposed evidence for the
role of an underlying latent infection in sar-
coidosis, patients generally do not demon-
strate any increased risk of mycobacterial
disease  or  other  opportunistic  infections
while receiving such therapies [47,56]. Ad-
ditionally, for the most part, antimicrobials
have not been shown to be helpful in the
management of sarcoidosis, with the excep-
tion  of  tetracyclines  and  antimalarials,
which have a limited role in the treatment of
cutaneous sarcoidosis. However, these par-
ticular antimicrobials also have anti-inflam-
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crobial mechanisms of action and generally
do not mitigate the need for concomitant
corticosteroid therapy for the treatment of
the systemic aspects of sarcoidosis [57,58].
Although these findings make an active
infection seem unlikely in sarcoidosis, there
is evidence that sarcoidosis may be trans-
missible. Bone marrow transplants from pa-
tients  with  sarcoidosis  have  resulted  in
granulomatous inflammation in recipients
[59,60]. Donor macrophages also have been
shown to be the origin of granulomatous in-
flammation in the allograft of a heart trans-
plant recipient who subsequently developed
recurrent cardiac sarcoidosis [61]. While
these examples do not directly indicate ac-
tive infection, they do suggest that the incit-
ing agent in sarcoidosis may be an antigen
contained within mononuclear phagocytes.
One plausible explanation of these phenom-
ena is that the immune system effectively
overcomes an inciting infection, but is un-
able to completely clear the organism, leav-
ing behind organism remnants (which may
be intracellular) to serve as antigens and po-
tentially act as niduses for granuloma for-
mation. 
non-infEctiouS EtiologiES
There are several proposed non-infec-
tious causes for sarcoidosis, notably expo-
sures  to  various  environmental  agents.
Multiple environmental and occupational ex-
posures have been reported to confer in-
creased risk of sarcoidosis, including organic
dusts,  solvents,  mold/mildew,  pesticides,
wood stoves, and others [1,7,8,62]. Also of
interest is the fact that in the first year fol-
lowing the World Trade Center disaster, New
York City firefighters developed sarcoidosis
at significantly higher than normal rates [63].
Some of these exposures however, are asso-
ciated with increased environmental microbe
exposure and thus are not specific for non-
infectious agents. The ACCESS study iden-
tified  modestly  positive  and  negative
relationships  between  multiple  exposures
and sarcoidosis, but a puzzling finding was
that occupational metal dust/metal fume ex-
posures were associated with decreased risk
of sarcoidosis in the study group, especially
in light of the fact that exposures to metals
such as beryllium are known to cause pul-
monary granulomas that are histologically
identical to those observed in sarcoidosis
[7,8,64,65]. 
Known exposure-related granulomatous
disorders (e.g., berylliosis) are considered
separate from sarcoidosis, but the role of yet
unidentified organic or inorganic dusts as po-
tential etiologic agents in sarcoidosis remains
possible. One hypothesis is that sarcoidosis
may be caused by a dysregulated immune re-
sponse to nanoparticulates (<1ʼm) derived
from common metals and minerals in the en-
vironment [66]. It is proposed that due to
their size, their presence cannot be reliably
demonstrated in sarcoid lesions with avail-
able methods. The shortcomings of dusts as
a sole cause of sarcoidosis are primarily re-
lated to the extra-pulmonary manifestations
of sarcoidosis, since extra-pulmonary organ
involvement is not a prominent feature of
berylliosis or other known dust exposures. 
concluSionS
Despite advances in our understanding
of the pathophysiology of sarcoidosis, de-
finitive etiologic agents or specific patho-
physiologic mechanisms underpinning this
disorder remain elusive. Furthermore, there
have been no definitive, reproducible trials
allowing clarification of such issues. It is
clear, though, that sarcoidosis develops in
individuals with an immunogenetic predis-
position to the disease, many occupational
and environmental exposures confer an in-
creased risk for developing sarcoidosis, and
the underlying inflammatory process is an
antigen-driven, strongly polarized Th1 im-
mune response. A large body of evidence
supports the role of a mycobacterial organ-
ism and possibly of P. acnes, but few other
organisms  have  been  as  heavily  studied.
This supports that infections do participate
in the pathogenesis of sarcoidosis, but the
exact role infections play in the underlying
mechanism of disease remains to be eluci-
dated.  Aside  from  establishing  a  direct
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pathogen, one possibility is that there are
multiple triggers required for the develop-
ment of sarcoidosis, such as a preceding
viral infection that primes an overactive im-
mune response, which then responds to a
secondary microbial organism or environ-
mental agent, with a subsequent granuloma-
tous reaction.
The  inability  to  identify  a  single
“cause” of sarcoidosis, as well as the wide
variability of disease course and manifesta-
tions, suggests that sarcoidosis may repre-
sent a heterogeneous spectrum of disorders,
caused by a complex interplay of a variety of
host factors, infectious processes, and non-
infectious environmental exposures that re-
sults in a final common pathway to systemic
granulomatous inflammation. A plausible
hypothesis is that multiple different anti-
gens, when introduced to a host with a sus-
ceptible genetic background and appropriate
immunologic milieu, may be capable of in-
ducing this aberrant immune response. Fur-
ther studies are necessary to understand the
etiology of sarcoidosis, and we are hopeful
that future work will help unravel the patho-
physiology of this highly complicated and
mysterious disorder.
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